Lantheus Holdings (LNTH) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Lantheus Holdings

NasdaqGM•Healthcare•Drug Manufacturers - Specialty & Generic

$100.54-0.19(<0.01%)Pre-market

Market Cap

$6.55B

P/E

23.8x

P/S

4.2x

P/B

5.0x

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

How this company scores

ExcellentMetricSide Score: 80/100

Strongest: Balance Sheet & Red Flags (25/25); weakest: Growth (15/25).

Profitability24/25

Growth15/25

Balance Sheet & Red Flags25/25

Cash & Earnings Quality16/25

Strengths

Strong marginsHigh ROELow leverageInterest easily covered

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 23.8x5y range 9.0x – 169.9x

Currently near its 16-quarter median.

P/S · 4.2x5y range 2.2x – 7.0x

Currently near its 20-quarter median.

P/B · 5.0x5y range 3.0x – 12.3x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

Operating margins dropped 32.5% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.

Price & Volume

Market Cap $6.55B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $1.56B
Q. Revenue: $388.18M
TTM EBITDA: $390.85M
TTM Op. Income: $302.34M
Q. Op. Income: $100.22M
TTM Net Income: $275.31M
Q. Net Income: $75.03M
EPS: $1.15
Shares Out.: $65.16M

$1.56B in TTM revenue grew 2.3% YoY, reaching $388.18M last quarter. TTM EBITDA of $390.85M and TTM operating income of $302.34M show growth is flowing through to the bottom line. TTM net income of $275.31M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 4 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 62.3%
EBITDA Margin: 31.6%
Op. Margin: 25.8%
Net Margin: 19.3%

Op. margin of 25.8% is up 2.5% YoY — cost efficiency is improving. Net margin at 19.3% and gross margin of 62.3% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 3 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 23.8x
P/S Ratio: 4.2x
P/B Ratio: 5.0x

At 23.8x P/E, the stock trades within typical market levels. P/S of 4.2x and P/B of 5.0x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is up 15% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $2.41B
Cash: $593.30M
Long-Term Debt: $570.35M
Book Value: $1.31B
D/E Ratio: 0.4
Debt/EBITDA: 4.6

With $2.41B in assets and $570.35M in long-term debt, D/E is 0.4and book value is $1.31B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 2 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $92.20M
TTM Free Cash Flow: $387.83M
FCF Margin: 24.9%
FCF / Net Income: 1.4

TTM FCF of $387.83M on $92.20M in operating cash flow. The FCF / Net Income ratio of 1.4x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 2 consecutive quarters — an improving trend.